Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Frequently asked questions
What sector does Denali Therapeutics Inc (DNLI) operate in?
Denali Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Denali Therapeutics Inc (DNLI) current stock price?
As of the latest data, Denali Therapeutics Inc stock price is $24.83, with a previous close of $24.73. Denali Therapeutics Inc gained $0.10 in the last trading session, representing a 0.4% increase.
What is Denali Therapeutics Inc (DNLI) current market capitalization?
Denali Therapeutics Inc market cap is approximately 3.94 billion.
What is Denali Therapeutics Inc (DNLI) Earnings Per Share (EPS)?
The trailing EPS is -$2.88, and the forward EPS is -$2.53.
What is Denali Therapeutics Inc (DNLI) EBITDA?
Denali Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -125.60 million.
Does Denali Therapeutics Inc (DNLI) pay dividends?
No. Denali Therapeutics Inc does not pay a dividend.
When is Denali Therapeutics Inc (DNLI) next earnings report?
Denali Therapeutics Inc is expected to release its next earnings report on June 30, 2026.
What is Denali Therapeutics Inc (DNLI) beta (volatility) score?
Denali Therapeutics Inc has a beta of 0.963, meaning its volatility is roughly in line with the market.
